Yissum - Research Development Company of the Hebrew University

Novel Cathepsin Targeted Agents for Molecular Imaging of Cancer and Atherosclerosis

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology


Cathepsin Targeted Computed Tomography X-Ray Contrast Agents for Molecular Imaging of Cancer and atherosclerosis
Project ID : 19-2016-4281

Yissum - Research Development Company of the Hebrew University
Yissum - Research Development Company of the Hebrew University

Description of the technology


Life Sciences and Biotechnology


Cathespin, Molecular Imaging, Cancer, CT, Computed Tomography,

Current development stage

TRL3 - Hypothesis testing and initial POC demonstrated in-vivo


X-ray computed tomography (CT) instruments are among the most available, efficient and cost-effective imaging modalities in hospitals. The field of CT molecular imaging agents is emerging relying mainly on detection of gold and bismuth nanoparticles, iodine and gadolinium labeled compounds. However, the low sensitivity of CT scanners to contrast reagents makes this a challenging task.

Our Innovation

The inventors have developed novel chemical routes for the synthesis of compounds that involve solid and solution phase chemistries, which provides the means for increasing the number of imaging moieties on a single compound, and achieve an informative and accurate CT signal.


These novel probes enable detection of the elevated cathepsin activity within cancerous tissue using a CT instrument.

Figure1 GNP–based compounds; TEM images of 100nm

Research Outlook

Compounds of the invention selectively recognize a target enzyme, present either within a cell or secreted from cells, and undergo interaction with the target enzyme. By conjugation or enzyme association at locations of high enzyme expression, a sufficient CT signal (above normal tissue background) from multiple imaging moieties may be detected, enabling accurate localization of the target enzyme. The enzyme localities are typically indicative of a condition associated with increased expression of the enzyme, e.g., a cathepsin. Such accumulation of compounds of the invention in such locations results in an amplified imaging signal, which provides an indication of a pathology.

Figure 2 Docking of a novel fluorescent probes to its target cathepsin L


The major causes of death in the Western world are cardiovascular diseases and cancer. More accurate detection of these diseases will improve clinical outcomes.

The compounds of the invention may be utilized in a variety of applications: in CT imaging, in the diagnosis of a pathological condition characterized by increased cathepsin, and others. The compound also be utilized for imaging a region or organ after or during treatment. This helps to assess the severity of the disease (e.g. enabling determination of treatment effectiveness and continued treatment approach).

Project manager

Mel Larrosa
VP Business Development Healthcare

Project researchers

Galia Blum
HUJI, School of Medicine - IMRIC
School of Pharmacy- Institute for Drug Research

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Agro and Marine biotech
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • Life Science & Biotechnology
  • medical imaging

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.